FI
FibroBiologics, Inc.
StreetZero Signal 60
About FibroBiologics, Inc.
FibroBiologics, Inc. is a pharmaceuticals company headquartered in Houston, TX and publicly traded on Nasdaq under ticker FBLG. It has raised a total of $145M over 7 rounds with its latest round being a $30M post-ipo equity financing on Mar 31, 2026. The company attended the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Jun 30, 2026. Its revenue is estimated in the $1M-$10M range.
LATEST FUNDINGPrivate Placement
$500K
Announced 2026-09-16
TOTAL RAISED$145M
IN THE NEWS
EMPLOYEES—
FOUNDED—
HQHouston, TX, USA
Industry
Pharmaceuticals
Tags
PharmaceuticalsPublicCell Therapy
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Total funding of $145M across 7 rounds
- Latest $30M post-ipo equity round on Mar 31, 2026
- Nasdaq-listed as FBLG
- Participated in H.C. Wainwright Cell Therapy Virtual Conference
- Houston, TX headquarters
Ask StreetZero about FibroBiologics, Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account